Dopamine News and Research

Latest Dopamine News and Research

Phase III trial results show cariprazine effective in treating negative symptoms associated with schizophrenia

Results of a clinical trial seem to show the first effective treatment for the negative symptoms - withdrawal, lack of emotion, and apathy - associated with schizophrenia.

31 Aug 2015

Single dose of cocaine can impair ability to recognise negative emotions

A single dose of cocaine can interfere with the ability to recognise negative emotions, according to new research presented at the ECNP conference in Amsterdam.

31 Aug 2015

Brain cells in Parkinson's disease die prematurely, burning out like an overheating motor

The death of brain cells in Parkinson's disease may be caused by a form of cellular energy crisis in neurons that require unusually high quantities of energy to carry out their job of regulating movement, researchers at the University of Montreal reported today.

28 Aug 2015

NTNU researchers find link between aggression and gene variant in children

Some children react more strongly to negative experiences than others. Researchers from the Norwegian University of Science and Technology have found a link between aggression and variants of a particular gene.

27 Aug 2015

Researchers examine relationship between energy needs and 'pleasure' of eating in food intake

A team at the Laboratoire biologie fonctionnelle et adaptative (CNRS/Université Paris Diderot) investigated the relative role of energy needs and "pleasure" of eating in food intake. The researchers studied a group of neurons in mice. They observed that when the neuron activity is compromised, feeding behavior becomes less related to the body's metabolic needs and more dependent on food palatability.

24 Aug 2015

Adolescent e-cigarette users more likely to start smoking

As e-cigarette usage among high school students continues to climb, a recent study from The Journal of the American Medical Association reveals an unsettling trend: that adolescent e-cigarette users are more likely than their non-vaping peers to initiate use of combustible tobacco products such as cigarettes, cigars and hookahs. The reason may lie in a common denominator between e-cigarettes and their combustible counterparts: nicotine.

21 Aug 2015

Two proteins that help cells eliminate trash may contribute to development of Parkinson's disease

Two proteins that share the ability to help cells deal with their trash appear to need each other to do their jobs and when they don't connect, it appears to contribute to development of Parkinson's disease, scientists report.

21 Aug 2015

S1 Biopharma supports FDA's approval of flibanserin for women living with HSDD

S1 Biopharma is a developer of first-in-class drugs for sexual dysfunction in both women and men. The company's lead compound, Lorexys, is currently in Phase IIb for the treatment of hypoactive sexual desire disorder (HSDD).

20 Aug 2015

IQWiG finds no added benefit for safinamide in Parkinson disease

Safinamide (trade name: Xadago) has been available since February 2015 as add-on therapy for the treatment of mid- to late-stage Parkinson disease in adults. In combination with levodopa alone or together with other Parkinson disease medicinal products, this monoamine oxidase (MAO-B) inhibitor is used to help restore dopamine levels in the brain.

20 Aug 2015

New prescription smoking-cessation drug not helping smokers quit

The introduction of a new prescription smoking-cessation aid, varenicline, in 2006 has had no significant impact on the rate at which Americans age 18 and older successfully quit smoking, according to a study led by researchers at University of California, San Diego School of Medicine.

18 Aug 2015

New research identifies cause of disruption in brain's communication channels linked to psychiatric disorders

New research has identified the mechanisms that trigger disruption in the brain's communication channels linked to symptoms in psychiatric disorders including schizophrenia. The University of Bristol study, published today [17 Aug] in the Proceedings of National Academy of Sciences, could have important implications for treating symptoms of brain disorders.

18 Aug 2015

Tracking retinal changes may help doctors to adjust schizophrenia treatment in the future

Schizophrenia is associated with structural and functional alterations of the visual system, including specific structural changes in the eye. Tracking such changes may provide new measures of risk for, and progression of the disease, according to a literature review published online in the journal Schizophrenia Research: Cognition, authored by researchers at New York Eye and Ear Infirmary of Mount Sinai and Rutgers University.

18 Aug 2015

Putaminal serotonergic innervation flags levodopa-induced dyskinesia risk

Increased serotonergic fibre innervation relative to dopaminergic fibre availability may be a potential marker of disease progression in Parkinson’s disease patients and a possible warning of levodopa-induced dyskinesia, indicates an in vivo imaging study.

17 Aug 2015

FDA accepts Chiasma's NDA filing for octreotide capsules for treatment of adult patients with acromegaly

Chiasma, Inc., a U.S. late-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration has accepted for filing the Company's New Drug Application (NDA) for the marketing and sale of octreotide capsules, an oral drug proposed for the maintenance therapy of adult patients with acromegaly.

17 Aug 2015

Algorithm encompassing clinical and genetic factors predicts PD

Researchers have devised a model that distinguishes patients with Parkinson’s disease from those without the condition without relying on motor features.

14 Aug 2015

Prion protein could play a role in depression

The discovery of antidepressant drugs in the 1950s led to the first biochemical hypothesis of depression, known as the monoamine hypothesis. This hypothesis proposes that an imbalance of certain brain chemicals is the key cause of depression.

14 Aug 2015

Neurocrine completes enrollment in Phase III clinical trial of NBI-98854 in tardive dyskinesia patients

Neurocrine Biosciences, Inc. announced today that it has recently completed subject randomization of the Phase III clinical trial (Kinect 3 Study) of its proprietary Vesicular Mono-Amine Transporter 2 (VMAT2) compound NBI-98854 in tardive dyskinesia patients.

13 Aug 2015

Researchers report role of two gene-regulating molecules in Parkinson's disease

As Parkinson's disease progresses in patients, a puzzling dichotomy plays out in their brains. One set of neurons degenerates, while a similar population nearby is spared the same degree of damage. Why the difference? An answer to this question could clear the way for preventions and treatments for this disease, which impairs movement.

11 Aug 2015

McGill researchers identify brain structures involved in delayed gratification

Researchers at McGill have clearly identified, for the first time, the specific parts of the brain involved in decisions that call for delayed gratification. In a paper recently published in the European Journal of Neuroscience, they demonstrated that the hippocampus (associated with memory) and the nucleus accumbens (associated with pleasure) work together in making critical decisions of this type, where time plays a role.

5 Aug 2015

University of Southampton research finds that electric fields alter behaviour of fruit flies

A new piece of research led by the University of Southampton has found that the behaviour of fruit flies, which are commonly used in laboratory experiments, is altered by electric fields.

31 Jul 2015

Dopamine News and Research

Latest Dopamine News and Research

Phase III trial results show cariprazine effective in treating negative symptoms associated with schizophrenia

Single dose of cocaine can impair ability to recognise negative emotions

Brain cells in Parkinson's disease die prematurely, burning out like an overheating motor

NTNU researchers find link between aggression and gene variant in children

Researchers examine relationship between energy needs and 'pleasure' of eating in food intake

Adolescent e-cigarette users more likely to start smoking

Two proteins that help cells eliminate trash may contribute to development of Parkinson's disease

S1 Biopharma supports FDA's approval of flibanserin for women living with HSDD

IQWiG finds no added benefit for safinamide in Parkinson disease

New prescription smoking-cessation drug not helping smokers quit

New research identifies cause of disruption in brain's communication channels linked to psychiatric disorders

Tracking retinal changes may help doctors to adjust schizophrenia treatment in the future

Putaminal serotonergic innervation flags levodopa-induced dyskinesia risk

FDA accepts Chiasma's NDA filing for octreotide capsules for treatment of adult patients with acromegaly

Algorithm encompassing clinical and genetic factors predicts PD

Prion protein could play a role in depression

Neurocrine completes enrollment in Phase III clinical trial of NBI-98854 in tardive dyskinesia patients

Researchers report role of two gene-regulating molecules in Parkinson's disease

McGill researchers identify brain structures involved in delayed gratification

University of Southampton research finds that electric fields alter behaviour of fruit flies

Quality, Patient Safety and Innovation Manager at Elsevier

How Bruker worked with the University of Manchester on mapping the dynamics of complex protein

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Dopamine News and Research

Latest Dopamine News and Research

Quality, Patient Safety and Innovation Manager at Elsevier

How Bruker worked with the University of Manchester on mapping the dynamics of complex protein

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Newsletters you may be interested in